gvtcx

Appointment of Contract Development and Manufacturing Organization (CDMO) for Vaccine Production

Public Health England Published 15 Jun 2020 Contracts Finder

key details

Value£1,250,000
Statuscomplete
Category (CPV) 73111000
Deadline31 Dec 2019
Contract start14 Jan 2020
Contract end31 Mar 2021
Procedurelimited
SME suitableYes
OCIDocds-b5fd17-b683e8fc-0e11-4493-ba62-2bbc72c4bdee

Award

SupplierValueDateStatus
ABL Europe SAS £1,250,000 30 Dec 2019 active

description

Public Health England (PHE) has awarded a contract to ABL Europe SAS to provide comprehensive services supporting vaccine development through its manufacturing. The project required establishing manufacturing conditions based on existing knowledge of Modified Vaccinia Ankara (MVA) viral vector production and quality control (QC) testing, to support Good Manufacturing Practice (GMP) release of drug product by end of Q1 / early Q2 2021.

The contract was awarded following extensive market research and publication of Voluntary Ex ante Transparency Notice (VEAT) notice in Official Journal of European Union (OJEU) - reference # 2019-042862 (document number 2019/S 245-603016).

The contract is until 31.03.21 with an option of 2 extensions of 12 months each.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
15 Jun 2020 Award (award) · 35a629a5-5b7f-417c-aa98-ab9b8edf5f46-364174

more from Public Health England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.